Arcutis officer Watanabe proposes $139K share sale

The listed aggregate market value is $139,466.1, alongside a share-outstanding figure of 125,691,961.

Available on EDGAR 11/02/2026 - 05:29 PM EST Accepted by SEC EDGAR 11/02/2026 - 05:29 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe reported a proposed sale of 4,377 common shares, with an approximate sale date of November 2, 2026. Merrill Lynch is listed as the broker, and NASDAQ as the exchange. The shares are listed as acquired through restricted stock vesting on November 1, 2026.

Key Figures

Proposed sale: 4,377 common shares Aggregate market value: $139,466.1 Shares outstanding: 125,691,961 shares +1 more

4 metrics

Proposed sale 4,377 common shares Approximate sale date November 2, 2026

Aggregate market value $139,466.1 Proposed sale

Shares outstanding 125,691,961 shares Shares outstanding figure

Acquisition date November 1, 2026 Restricted stock vesting

Key Terms

Rule 144, Restricted Stock Vesting, aggregated

3 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

aggregated regulatory

"sales are required by paragraph (e) of Rule 144 to be aggregated"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARQT shares does Todd Franklin Watanabe plan to sell?

The proposed sale for Todd Franklin Watanabe, an Arcutis Biotherapeutics, Inc. officer, covers 4,377 common shares, with an approximate sale date of November 2, 2026; Merrill Lynch is listed as broker.

What is the listed market value of Todd Franklin Watanabe's ARQT share sale?

The listed aggregate market value for Todd Franklin Watanabe's 4,377 common shares is $139,466.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801061
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Todd Franklin Watanabe
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	4377	139466.1	125691961	11/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			4377	11/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Todd Franklin Watanabe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)